Tuesday, December 16, 2025 12/16/2025

Assessment of restoration of an internally deleted dystrophin as a surrogate biomarker for future clinical trials of a gene editing therapy in Duchenne muscular dystrophy

Award Number: R21HD117763
ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2025
PERIOD OF PERFORMANCE END DATE: 08/31/2027

Group Awards By:

View Award Description

Assessment of restoration of an internally deleted dystrophin as a surrogate biomarker for future clinical trials of a gene editing therapy in Duchenne muscular dystrophy - Project Summary Duchenne muscular dystrophy is a rare genetic muscle disease affecting ~16,000 patients in the US. It leads to premature death in the twenties to thirties and has no cure. Gene editing offers an innovative solution for Duchenne since it can be used to permanently remove patient mutations in the endogenous gene and restore an internally-deleted and functional dystrophin protein. The gene editing therapy described here, MyoDys45-55, uses adeno-associated virus (AAV) delivery of CRISPR/Cas9 to delete exons 45-55 in the DMD gene, correcting the reading frame for 50% of all Duchenne patients. The restored dystrophin is three times larger than the mini/micro- dystrophins introduced by gene replacement and is associated with a very mild or asymptomatic form of Becker muscular dystrophy. As MyoDys45-55 progresses towards clinical trials, preclinical data are critically needed to characterize the relationship between the amount of restored dystrophin and improvements in function. Here, pups from a humanized mouse model of Duchenne will be administered a range of AAV9-MyoDys45-55 doses and non-invasive functional testing, physiology, and quantification of molecular outcomes will be conducted. Analysis will be performed to assess how restoration of the gene edited dystrophin protein correlates to functional benefit. These data will be used to inform trial design (including dose selection) and to support the use of the exon 45-55 deleted dystrophin as a clinical biomarker and potential surrogate endpoint for accelerated approval. Importantly, there is clear regulatory precedent for this pathway since five other Duchenne drugs have received accelerated approval based on expression of different internally-deleted dystrophins. But FDA has also stressed the need for program-specific preclinical and clinical evidence. Here we will perform these preclinical studies to support clinical trials that we will initiate in the near future. This work is critical to advance MyoDys45-55 to patients as an innovative solution for a large proportion of the Duchenne population.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	MYOGENE BIO LLC	7098 MIRATECH DR STE 120	SAN DIEGO	CA	92121	SAN DIEGO	USA	Child Health and Human Development Extramural Research	000	1	11/19/2025	NEW	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $302,500 )
2025	2025	MYOGENE BIO LLC	7098 MIRATECH DR STE 120	SAN DIEGO	CA	92121	SAN DIEGO	USA	Child Health and Human Development Extramural Research	000	1	8/20/2025	NEW	$302,500
														Subtotal = $302,500

Grand Total All Awards = $302,500

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Assessment of restoration of an internally deleted dystrophin as a surrogate biomarker for future clinical trials of a gene editing therapy in Duchenne muscular dystrophy

Award Number: R21HD117763

ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2025

PERIOD OF PERFORMANCE END DATE: 08/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer